Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in glycopeptide antibacterials.

John F Barrett1

  • 1Merck Research Laboratories, Rahway, NJ 07065, USA. john_barrett2@merck.com

Current Opinion in Investigational Drugs (London, England : 2000)
|August 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibacterial and mechanism of action studies of boxazomycin A.

The Journal of antibiotics·2024
Same author

Overview of anti-infective drug development.

Current protocols in pharmacology·2011
Same author

Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa.

Journal of natural products·2009
Same author

Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa.

Bioorganic & medicinal chemistry·2008
Same author

Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347.

Journal of the American Chemical Society·2008
Same author

Control and prevention of MRSA infections.

Methods in molecular biology (Clifton, N.J.)·2007
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

New glycopeptide antibiotics like dalbavancin are crucial for treating severe Gram-positive infections, especially those resistant to vancomycin. These agents offer unique profiles to combat rising antibiotic resistance.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Glycopeptide antibiotics (vancomycin, teicoplanin) are mainstays for severe Gram-positive infections.
  • Increasing vancomycin resistance in enterococci and staphylococci necessitates new therapeutic options.

Purpose of the Study:

  • To identify and evaluate novel glycopeptide derivatives with activity against resistant Gram-positive strains.
  • To address the unmet medical need for effective treatments against vancomycin-resistant bacteria.

Main Methods:

  • Review of existing literature on glycopeptide antibiotics.
  • Analysis of microbiological and pharmacological profiles of emerging glycopeptide candidates.

Main Results:

Related Experiment Videos

  • Dalbavancin, oritavancin, telavancin, and ramoplanin are identified as leading development candidates.
  • These agents demonstrate unique characteristics to combat resistant Gram-positive infections.

    • Conclusions:

    • Novel glycopeptides are essential to overcome vancomycin resistance.
    • Emerging agents offer promising therapeutic strategies for challenging infections.